HLB Group said on the 31st that it has hired former Samsung Biologics CEO Kim Tae-han as chairman overseeing the institutional sector of biotech. Kim's term begins Jan. 1 next year.
Chairman Kim led planning and new-business strategy at key Samsung Group affiliates, steering groupwide visions for future businesses. He was later appointed the first CEO of Samsung Biologics and led core growth phases from the company's founding to its initial public offering (IPO), global roadshows, and securing overseas clients.
HLB Group is awaiting U.S. Food and Drug Administration (FDA) approval procedures for a liver cancer therapy combining Rivoceranib and Camrelizumab and for the lirafugratinib bile duct cancer therapy. HLB Group expects Kim's management ability and broad experience to be a great help.
Chairman Kim said, "I will help advance the business structure so that research and development results do not remain one-off achievements but lead to sustainable value for corporations."